Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection

HIV Medicine

Volumn 13, Issue 2, 2012, Pages 127-131

  Rockstroh, J K ^a   Teppler, H ^b   Zhao, J ^b   Sklar, P ^b   Harvey, C M ^b   Strohmaier, K M ^b   Leavitt, R Y ^b   Nguyen, B Y T ^b  

^a UNIVERSITY OF BONN   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

BENCHMRK; Hepatitis coinfection; HIV 1; Raltegravir; STARTMRK

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; PLACEBO; RALTEGRAVIR; VIRUS RNA;

ADULT; ANTIBODY BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; BEDTIME DOSAGE; BILE DUCT STONE; CHOLANGITIS; CHOLECYSTITIS; CHOLELITHIASIS; CHOLESTASIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FATTY LIVER; FEMALE; GALLBLADDER DISEASE; GALLBLADDER POLYP; HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; JAUNDICE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER PAIN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; COINFECTION; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRROLIDINONES; TREATMENT OUTCOME;

EID: 84255173474     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00933.x     Document Type: Article

References (18)

1. Alter M. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6-S9.
2. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48: 353-367.
3. Rockstroh JK, Mocroft A, Soriano Vet al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002.
4. Nikolopoulos GK, Paraskevis D, Hatzitheodorou Eet al. Impact of hepatitis B infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analyses. Clin Infect Dis 2009; 48: 1763-1771.
5. Rosenthal E, Pialoux G, Bernard Net al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007; 14: 183-188.
6. Weber R, Sabin CA, Friis-Moller Net al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641.
7. Nunez M, Lana R, Mendoza JLet al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 426-431.
8. Bonfanti P, Landonio S, Ricci Eet al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 316-318.
9. Wit FW, Weverling GJ, Weel Jet al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23-31.
10. Servoss JC, Kitch DW, Andersen JWet al. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr 2006; 43: 320-323.
11. Lennox JL, DeJesus E, Lazzarin Aet al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
12. Lennox JL, DeJesus E, Berger DSet al. Raltegravir-based compared to efavirenz-based regimens in treatment-naive HIV-1 infected patients: efficacy, durability, subgroup, safety, and metabolic analyses through 96 weeks of follow-up. J Acquir Immune Defic Syndr 2010; 55: 39-48.
13. Steigbigel RT, Cooper DA, Kumar PNet al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-354.
14. Steigbigel RT, Cooper DA, Teppler Het al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50: 605-612.
15. Kassahun K, McIntosh I, Cui Det al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35: 1657-1663.
16. Iwamoto M, Hanley WE, Petry ASet al. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother 2009; 53: 1747-1752.
17. Rachlis A, Clotet V, Baxter J, Murphy R, Lefebvre E.Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials 2007; 8: 213-220.
18. Vispo E, Mena A, Maida Iet al. Hepatic safety profile of new antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Hepatol 2010; 52: S448.